0001209191-21-010477.txt : 20210212 0001209191-21-010477.hdr.sgml : 20210212 20210212200015 ACCESSION NUMBER: 0001209191-21-010477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RUBINSTEIN JULIE CENTRAL INDEX KEY: 0001780664 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 21631283 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-10 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780664 RUBINSTEIN JULIE C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 0 1 0 0 President Common Stock 2021-02-10 4 M 0 15000 6.55 A 15000 D Common Stock 2021-02-10 4 S 0 6770 62.14 D 8230 D Common Stock 2021-02-10 4 S 0 3814 63.00 D 4416 D Common Stock 2021-02-10 4 S 0 3798 64.09 D 618 D Common Stock 2021-02-10 4 S 0 618 64.76 D 0 D Common Stock 2021-02-11 4 M 0 15000 6.55 A 15000 D Common Stock 2021-02-11 4 S 0 10729 63.12 D 4271 D Common Stock 2021-02-11 4 S 0 4271 63.67 D 0 D Stock Option (Right to Buy) 6.55 2021-02-10 4 M 0 15000 0.00 D 2028-02-07 Common Stock 15000 375000 D Stock Option (Right to Buy) 6.55 2021-02-11 4 M 0 15000 0.00 D 2028-02-07 Common Stock 15000 360000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $61.60 to 62.58 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.60 to 63.42, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.60 to 64.58, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.60 to 64.90, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.51 to 63.50, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.51 to to 63.75, inclusive. The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Julie Rubinstein by Eric Billings, attorney-in-fact 2021-02-12